5-tert-butyl-3,4-dimethyl-3H-thiazol-2-ylideneamine | 15090-75-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-tert-butyl-3,4-dimethyl-3H-thiazol-2-ylideneamine
• 英文别名: 3,4-Dimethyl-5-tert-butylthiazolon-2-imide；3,4-Dimethyl-2-imino-5-t-butyl-thiazolin；5-t-Butyl-3,4-dimethyl-2-thiazolone imide；5-tert-butyl-3,4-dimethyl-1,3-thiazol-2-imine
• CAS: 15090-75-2
• 化学式: C₉H₁₆N₂S
• 分子量: 184.305
• InChiKey: MSIVAJXWEOCQRR-UHFFFAOYSA-N

物化性质

• 沸点：
  130-132 °C(Press: 3-4 Torr)
• 密度：
  1.053 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-tert-butyl-3,4-dimethyl-3H-thiazol-2-ylideneamine 、 水杨酸苯酯 反应 4.0h， 生成 N-(5-tert-butyl-3,4-dimethyl-3H-thiazol-2-ylidene)-2-hydroxy-benzamide
  参考文献：
  名称：

  2-氨基噻唑的烷基化

  摘要：

  DOI：

  10.1007/bf00944279
• 作为产物：
  描述：

  2-imino-3,4-dimethyl-2,3-dihydrothiazole 、 叔丁醇 在 硫酸 作用下， 反应 24.0h， 生成 5-tert-butyl-3,4-dimethyl-3H-thiazol-2-ylideneamine
  参考文献：
  名称：

  2-氨基噻唑的烷基化

  摘要：

  DOI：

  10.1007/bf00944279

文献信息

• IMINE COMPOUND
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1820504A1

  公开（公告）日：2007-08-22

  An imine compound represented by the formula: wherein A represents a heterocyclic group; R1, R2, an R3 each represent a hydrogen atom, a halogen atom, a C1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom (s), a C3-10 cycloalkyl group, a C1-6 haloalkyl group, a C1-10 alkoxy group, etc.; R4 represents an optionally substituted C1-10 alkyl, C2-6 alkenyl, or aryl group; R5 represents a hydrogen atom, a C1-10 alkoxy group, a C1-6 haloalkyl group, an optionally substituted C1-10 alkyl or C2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents -CO-, -CO-CO-, -CO-NH-, -CS-NH-, or -SO2-, or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient. The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

  本发明的亚胺化合物的化学式为：其中A代表杂环基团；R1、R2和R3分别代表氢原子、卤原子、一个C1-10烷基基团，该基团可以选择性地被芳基基团取代，该芳基基团被卤原子取代，一个C3-10环烷基基团，一个C1-6卤代烷基基团，一个C1-10烷氧基基团等；R4代表一个可以选择性取代的C1-10烷基、C2-6烯基或芳基基团；R5代表一个氢原子、一个C1-10烷氧基基团、一个C1-6卤代烷基基团、一个可以选择性取代的C1-10烷基或C2-6烯基基团、一个可以选择性取代的芳基或杂环基团等；W代表-CO-、-CO-CO-、-CO-NH-、-CS-NH-或-SO2-，或者一种包含上述亚胺化合物作为活性成分的大麻素受体激动剂。本发明的亚胺化合物具有大麻素受体激动剂效应，并且可用作治疗或预防疼痛和自身免疫疾病的药物。
• Imine Compound
  申请人：Saito Shiuji

  公开号：US20080312435A1

  公开（公告）日：2008-12-18

  An imine compound represented by the formula: wherein A represents a heterocyclic group; R 1 , R 2 , an R 3 each represent a hydrogen atom, a halogen atom, a C 1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom(s), a C 3-10 cycloalkyl group, a C 1-6 haloalkyl group, a C 1-10 alkoxy group, etc.; R 4 represents an optionally substituted C 1-10 alkyl, C 2-6 alkenyl, or aryl group; R 5 represents a hydrogen atom, a C 1-10 alkoxy group, a C 1-6 haloalkyl group, an optionally substituted C 1-10 alkyl or C 2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents —CO—, —CO—CO—, —CO—NH—, —CS—NH—, or —SO 2 —, or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient. The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

  一种以以下式表示的亚胺化合物：其中A代表杂环基团；R1、R2和R3分别表示氢原子、卤素原子、C1-10烷基，该烷基可选地取代有芳基，所述芳基取代有卤素原子，C3-10环烷基，C1-6卤代烷基，C1-10烷氧基等；R4表示可选地取代的C1-10烷基，C2-6烯基或芳基；R5表示氢原子，C1-10烷氧基，C1-6卤代烷基，可选地取代的C1-10烷基或C2-6烯基，可选地取代的芳基或杂环基团等；W表示—CO—，—CO—CO—，—CO—NH—，—CS—NH—或—SO2—，或以该亚胺化合物为活性成分的大麻素受体激动剂。本发明的亚胺化合物具有大麻素受体激动剂作用，可用作治疗或预防疼痛和自身免疫性疾病的药物。
• Alkylation of aminothiazoles
  作者：V. A. Krasovskii、S. I. Burmistrov

  DOI：10.1007/bf01031760

  日期：——
• Nuclease compositions and methods
  申请人：Davies Bryan W.

  公开号：US20100222410A1

  公开（公告）日：2010-09-02

  The present invention generally relates to various nucleases and uses thereof, and in some cases, to the UPF0054 protein superfamily. Members of the UPF0054 protein superfamily, such as the E. coli protein YbeY, may possess RNase activity and may be involved in certain important cellular processes. Disruption of YbeY activity can lead to increased sensitivity to antibiotics. Accordingly, certain embodiments of the invention are directed to systems and methods for screening target compounds for activity against UPF0054 superfamily proteins. In some embodiments, the screening method allows to target compositions to be determined that show selective activity against UPF0054 superfamily proteins. Other embodiments of the invention provide for nucleases capable of site-specific cleavage of nucleic acids.
• [EN] NUCLEASE COMPOSITIONS AND METHODS<br/>[FR] COMPOSITIONS DE NUCLÉASE ET PROCÉDÉS
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2010008585A2

  公开（公告）日：2010-01-21

  The present invention generally relates to various nucleases and uses thereof, and in some cases, to the UPF0054 protein superfamily. Members of the UPF0054 protein superfamily, such as the E. coli protein YbeY, may possess RNase activity and may be involved in certain important cellular processes. Disruption of YbeY activity can lead to increased sensitivity to antibiotics. Accordingly, certain embodiments of the invention are directed to systems and methods for screening target compounds for activity against UPF0054 superfamily proteins. In some embodiments, the screening method allows target compositions to be determined that show selective activity against UPF0054 superfamily proteins. Other embodiments of the invention provide for nucleases capable of site-specific cleavage of nucleic acids.